Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer

Bibliographic Details
Main Authors:	Mahon, K L, Lin, H-M, Castillo, L, Lee, B Y, Lee-Ng, M, Chatfield, M D, Chiam, K, Breit, S N, Brown, D A, Molloy, M P, Marx, G M, Pavlakis, N, Boyer, M J, Stockler, M R, Daly, R J, Henshall, S M, Horvath, L G
Format:	Online
Language:	English
Published:	Nature Publishing Group 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4402456/

Similar Items

Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer
by: Lin, H-M, et al.
Published: (2014)

Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer
by: Mahon, K L, et al.
Published: (2014)

Gemcitabine–oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed
by: Lee, J-L, et al.
Published: (2014)

Docetaxel in very elderly men with metastatic castration-resistant prostate cancer
by: Wong, Hui-Li, et al.
Published: (2015)

The Influence of Prednisone on the Efficacy of Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer
by: Teply, Benjamin A., et al.
Published: (2015)

Inhibition of Hsp90 Augments Docetaxel Therapy in Castrate Resistant Prostate Cancer
by: Ku, ShengYu, et al.
Published: (2014)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
by: Francini, Filippo, et al.
Published: (2011)

Enzalutamide (formerly MDV3100) prolongs survival in docetaxel-pretreated castration-resistant prostate cancer patients
by: Heck, Matthias M., et al.
Published: (2013)

Prospective Evaluation of Low-Dose Ketoconazole Plus Hydrocortisone (HC) in Docetaxel Pre-treated Castration-Resistant Prostate Cancer (CRPC) Patients
by: Lo, Ernest N., et al.
Published: (2015)

Whole blood defensin mRNA expression is a predictive biomarker of docetaxel response in castration-resistant prostate cancer
by: Kohli, Manish, et al.
Published: (2015)

Safety of enzalutamide in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel: Expanded access in North America
by: Joshua, Anthony M., et al.
Published: (2015)

Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)
by: Joseph M. Unger, et al.
Published: (2018-06-01)

Predictive Factors for Premature Discontinuation of Docetaxel-Based Systemic Chemotherapy in Men With Castration-Resistant Prostate Cancer
by: Park, Seung Chol, et al.
Published: (2013)

Activity of enzalutamide in men with metastatic castration resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel
by: Cheng, Heather H., et al.
Published: (2015)

Subverting ER-Stress towards Apoptosis by Nelfinavir and Curcumin Coexposure Augments Docetaxel Efficacy in Castration Resistant Prostate Cancer Cells
by: Mathur, Aditi, et al.
Published: (2014)

Docetaxel-Induced Fatal Interstitial Pneumonitis in a Patient with Castration-Resistant Prostate Cancer
by: Min, Byung-Dal, et al.
Published: (2012)

Quantitative analysis of castration resistant prostate cancer progression through phosphoproteome signaling
by: Lescarbeau, Reynald M, et al.
Published: (2014)

ERG induces taxane resistance in castration-resistant prostate cancer
by: Galletti, Giuseppe, et al.
Published: (2014)

Effect of simvastatin on castration-resistant prostate cancer cells
by: Kim, Jenny Hanbi, et al.
Published: (2014)

Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space
by: Sartor, A Oliver
Published: (2011)

Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience
by: Nakano, Kazuhiko, et al.
Published: (2012)

Therapeutic Options in Docetaxel-Refractory Metastatic Castration-Resistant Prostate Cancer: A Cost-Effectiveness Analysis
by: Zhong, Lixian, et al.
Published: (2013)

Low dose of interferon-α improves the clinical outcomes of docetaxel in patients with castration-resistant prostate cancer: A pilot study
by: LI, YUN-FEI, et al.
Published: (2014)

Risk Factors for Metastatic Castration-Resistant Prostate Cancer (CRPC) Predict Long-Term Treatment with Docetaxel
by: Kawahara, Takashi, et al.
Published: (2012)

External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer
by: Nakano, Kazuhiko, et al.
Published: (2014)

Metastatic castrate-resistant prostate cancer with a late, complete and durable response to docetaxel chemotherapy: a case report
by: Daverede, Luis, et al.
Published: (2014)

Synergistic Antitumor Activities of Docetaxel and Octreotide Associated with Apoptotic-Upregulation in Castration-Resistant Prostate Cancer
by: Zhu, Sha, et al.
Published: (2014)

Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel
by: Araujo, John C, et al.
Published: (2013)

Docetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer: A Case Report and Review of Literature
by: Di Lorenzo, Giuseppe, et al.
Published: (2016)

Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer
by: Salvi, Samanta, et al.
Published: (2016)

Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer
by: Jang, Ho Seong, et al.
Published: (2016)

Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy
by: Yamashita, Shimpei, et al.
Published: (2016)

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel
by: Chi, K. N., et al.
Published: (2016)

Targeting the MLL complex in castration resistant prostate cancer
by: Malik, Rohit, et al.
Published: (2015)

Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial
by: Tebbutt, N C, et al.
Published: (2013)

Hyperglycaemia-induced resistance to Docetaxel is negated by metformin: a role for IGFBP-2
by: Biernacka, K M, et al.
Published: (2016)

Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science
by: Nussbaum, N, et al.
Published: (2016)

Targeting molecular resistance in castration-resistant prostate cancer
by: Chandrasekar, Thenappan, et al.
Published: (2015)

Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
by: Chandrasekar, Thenappan, et al.
Published: (2015)

The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer
by: Grasso, Catherine S., et al.
Published: (2012)